Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. - Wikidata - wikimedia - TriplyDB

Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.

Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.

http://www.wikidata.org/entity/Q37369623

about

Infracentimetric HER-2 positive breast tumours-review of the literature Recent advances in the field of anti-cancer immunotherapy Cardiac toxicity in cancer survivors Evaluation and management of patients with heart disease and cancer: cardio-oncology Noninvasive imaging of cardiovascular injury related to the treatment of cancer Efficacy and learning curve of a hand-held echocardiography device in an oncology outpatient clinic: Expanding the use of echoscopic heart examination beyond cardiology Intersection of cardiology and oncology clinical practices.Immunological Approaches in the Treatment of Metastasized Breast Cancer Clinical practice guidelines for breast cancer rehabilitation: syntheses of guideline recommendations and qualitative appraisals.Genome-based risk prediction for early stage breast cancer.Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: a prospective observational study.Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Lifestyle interventions for cardiovascular risk reduction in women with breast cancer.Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer.Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer.Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.Heart failure and chemotherapeutic agents.Breast cancer therapy-associated cardiovascular disease.Update on cardiotoxicity of anti-cancer treatments.Assessment of biventricular systolic strain derived from the two-dimensional and three-dimensional speckle tracking echocardiography in lymphoma patients after anthracycline therapy.Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.Echocardiographic evaluation of cardiac function after cancer chemotherapy.Lack of uniformity in cardiac assessment during trastuzumab therapy.Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.The British Society of Echocardiography - a legacy of leadership.Detection of subclinical trastuzumab-induced cardiotoxicity in patients with breast cancer.Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.Investigation of the role of DNA methylation in the expression of ERBB2 in human myocardium.Chemotherapy-induced Cardiotoxicity.Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.Clinical outcomes and cardiac safety of continuous antiHer2 therapy in c-erbB2-positive metastatic breast cancer patients.

P2860

Q26774597-79F2C887-11E0-46AD-8E79-2BADD9A67F6E Q26775602-1A6DD1E0-0F81-4434-90BD-E3779D789435 Q26851957-1A417CD9-F8CE-47F7-A5FA-EACB8D6AE706 Q26998273-4DDE5982-CA67-474B-8CBA-63B738DD2ACB Q27024715-16C521A5-F197-4414-BB89-91750E12CF21 Q30406985-A83F5C7E-FD92-43C5-988F-3AAABB3980DA Q30428702-E7F52391-7C83-468B-B24C-2A4C9FD3356B Q34140043-1030E4B2-E3BB-447C-8B91-1B37C5AA360D Q34266960-C055B66A-9E37-4626-8B2A-C390C941B1AD Q34359289-7F451B00-FEDE-46DD-B054-53EF06C8024F Q34694972-BF30165D-A8D4-4200-9CD7-CEB832ED9654 Q34779675-44A4D068-4ACF-4E2C-B4E8-0B55911FF465 Q35687574-5E6C0387-3C61-44AF-9D97-BF871D5F516B Q35878469-95937884-2CDF-405A-923E-D3488BEA7965 Q35889261-8B5EC50F-C5D2-410A-BB6A-1D047D5B0101 Q35997676-C1D9EFAB-7D53-4AD6-BBD9-6D73E14C458E Q36207305-EB6AC9FD-99CD-4A20-916B-405842C1AEBB Q36988282-6D787C2D-05D6-4A58-BE2C-2A50B56B3B4C Q37116520-FB012F86-167A-48CC-A5CC-868BC982EBE2 Q37240194-D6032F79-E526-4FB2-8B3D-8424EAB61295 Q37547962-D8698C96-C9B3-4777-BFA8-9AA73B7ADD11 Q38416816-46C96FA6-8D09-49FA-AD7A-1F59A1CF97F9 Q38559133-CD836780-490A-4D44-98C7-FD11A11F5F39 Q38645182-0B6FD668-5342-41E4-96F6-F63227BC9D10 Q38686222-18A6204A-0CFD-4ABB-9E79-7AF9BD198031 Q38931763-192622CF-B754-4A8D-9AD3-C37E12B91DF2 Q39263764-E9ECD94B-7FA2-42FB-B40B-E3781E8EB5AF Q39429845-794AC017-AFEA-4408-975A-598AB7BBE46B Q39746124-1C09C45C-3742-43DA-B946-C33644B3101F Q41288150-000A5B96-4CC0-4B74-9C9B-7D7EA5055A4E Q42265816-A0EAA314-2817-4B31-9133-19B7CD4462CE Q42333822-D172818A-1C3B-4E6D-8612-E5577190CBE0 Q48344109-5628201F-9A40-4D54-A6B2-E77037D00198 Q49909927-8A368CA6-8724-48F1-B634-F573507A2449 Q50687140-AFE539F4-8A43-4FD5-A013-C4A98337CF0B Q50875570-2CC99B55-0FC1-4B88-A37E-E9E1063F6250 Q51224671-3B555D80-F99C-45CE-B8C8-B1FAC1985C41 Q51368192-51C661CE-98D9-4C9A-BADA-AA71C325AFA6 Q51737126-BD3B6B07-FBEC-47E7-941A-0923B90DB32D Q54368881-C7FF9613-B8F8-4DA9-850D-DC79D0E45022

P2860

Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.

http://www.wikidata.org/entity/Q37369623

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Minimizing cardiotoxicity whil ...... ew and expert recommendations.

@en

Minimizing cardiotoxicity whil ...... ew and expert recommendations.

@nl

type

label

Minimizing cardiotoxicity whil ...... ew and expert recommendations.

@en

Minimizing cardiotoxicity whil ...... ew and expert recommendations.

@nl

prefLabel

Minimizing cardiotoxicity whil ...... ew and expert recommendations.

@en

Minimizing cardiotoxicity whil ...... ew and expert recommendations.

@nl

P1433

Q37369623-60C2874E-44BE-4184-B9AC-EEB1B97B04F9

P1476

Q37369623-9F241540-1253-46C4-B0CA-51ED05891378

P2093

Q37369623-0A8B74CD-CD82-4FD9-8560-F3227C3D531F

Q37369623-199FC323-E8AB-47C4-928E-61C6CDE72F45

Q37369623-4B93F5E3-9D90-4F81-8D7E-AFAE289995F7

Q37369623-78B6179C-6926-4E85-93D2-78A244404CF3

Q37369623-9065B072-BDEA-4574-B7DA-B9C5ECF8F544

Q37369623-AA2202F8-C46A-4EF8-880C-FEAE5208C276

Q37369623-AD012C43-A348-4C84-B06D-3762C9943347

Q37369623-CAE1C748-53E6-4EAE-8ACD-6823DEB34D02

Q37369623-F90F2D77-FB10-4030-B1D8-5F453FA1356D

P304

Q37369623-DA56C26D-744F-4934-A44E-9D91B3BED674

P31

Q37369623-C255290D-C76D-4204-89FA-6F11BAFFADCC

P356

Q37369623-6A89DC6E-0A3C-4061-80A6-7283EB3BB83A

P433

Q37369623-A278629E-9579-45C5-9C84-8713E1818AD2

P478

Q37369623-02E5D980-6F64-4E93-8EED-709B2C2157C4

P577

Q37369623-41E93DAB-E330-4E84-8A44-8B60D56DA858

P5875

Q37369623-7FAD2629-A5D2-4047-8C21-5F9543FBE040

P698

Q37369623-5175A0F7-A6B0-495E-8CB6-38AB208F2E71

P356

THEONCOLOGIST.2008-0137

P1433

P1476

Minimizing cardiotoxicity whil ...... ew and expert recommendations.

@en

P2093

Antonia Márquez

http://www.w3.org/2001/XMLSchema#string

Bijoy Khandheria

http://www.w3.org/2001/XMLSchema#string

Emilio Alba

http://www.w3.org/2001/XMLSchema#string

Francisco J Esteva

http://www.w3.org/2001/XMLSchema#string

José Angel García-Sáenz

http://www.w3.org/2001/XMLSchema#string

José Zamorano

http://www.w3.org/2001/XMLSchema#string

Leopoldo Pérez-Isla

http://www.w3.org/2001/XMLSchema#string

Miguel Martín

http://www.w3.org/2001/XMLSchema#string

Partho Sengupta

http://www.w3.org/2001/XMLSchema#string

P304

1-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2008-0137

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23791632

http://www.w3.org/2001/XMLSchema#string

P698

19147689

http://www.w3.org/2001/XMLSchema#string